RATIONALE: Classical interpretation of cystic fibrosis (CF) lung disease pathogenesis suggests that infection initiates disease progression, leading to an exuberant inflammatory response, excessive mucus, and ultimately bronchiectasis. Although symptomatic antibiotic treatment controls lung infections early in disease, lifelong bacterial residence typically ensues. Processes that control the establishment of persistent bacteria in the CF lung, and the contribution of noninfectious components to disease pathogenesis, are poorly understood. OBJECTIVES: To evaluate whether continuous antibiotic therapy protects the CF lung from disease using a ferret model that rapidly acquires lethal bacterial lung infections in the absence of antibiotics. METHODS: CFTR (cystic fibrosis transmembrane conductance regulator)-knockout ferrets were treated with three antibiotics from birth to several years of age and lung disease was followed by quantitative computed tomography, BAL, and histopathology. Lung disease was compared with CFTR-knockout ferrets treated symptomatically with antibiotics. MEASUREMENTS AND MAIN RESULTS: Bronchiectasis was quantified from computed tomography images. BAL was evaluated for cellular differential and features of inflammatory cellular activation, bacteria, fungi, and quantitative proteomics. Semiquantitative histopathology was compared across experimental groups. We demonstrate that lifelong antibiotics can protect the CF ferret lung from infections for several years. Surprisingly, CF animals still developed hallmarks of structural bronchiectasis, neutrophil-mediated inflammation, and mucus accumulation, despite the lack of infection. Quantitative proteomics of BAL from CF and non-CF pairs demonstrated a mucoinflammatory signature in the CF lung dominated by Muc5B and neutrophil chemoattractants and products. CONCLUSIONS: These findings implicate mucoinflammatory processes in the CF lung as pathogenic in the absence of clinically apparent bacterial and fungal infections.
RATIONALE: Classical interpretation of cystic fibrosis (CF) lung disease pathogenesis suggests that infection initiates disease progression, leading to an exuberant inflammatory response, excessive mucus, and ultimately bronchiectasis. Although symptomatic antibiotic treatment controls lung infections early in disease, lifelong bacterial residence typically ensues. Processes that control the establishment of persistent bacteria in the CF lung, and the contribution of noninfectious components to disease pathogenesis, are poorly understood. OBJECTIVES: To evaluate whether continuous antibiotic therapy protects the CF lung from disease using a ferret model that rapidly acquires lethal bacterial lung infections in the absence of antibiotics. METHODS: CFTR (cystic fibrosis transmembrane conductance regulator)-knockout ferrets were treated with three antibiotics from birth to several years of age and lung disease was followed by quantitative computed tomography, BAL, and histopathology. Lung disease was compared with CFTR-knockout ferrets treated symptomatically with antibiotics. MEASUREMENTS AND MAIN RESULTS: Bronchiectasis was quantified from computed tomography images. BAL was evaluated for cellular differential and features of inflammatory cellular activation, bacteria, fungi, and quantitative proteomics. Semiquantitative histopathology was compared across experimental groups. We demonstrate that lifelong antibiotics can protect the CF ferret lung from infections for several years. Surprisingly, CF animals still developed hallmarks of structural bronchiectasis, neutrophil-mediated inflammation, and mucus accumulation, despite the lack of infection. Quantitative proteomics of BAL from CF and non-CF pairs demonstrated a mucoinflammatory signature in the CF lung dominated by Muc5B and neutrophil chemoattractants and products. CONCLUSIONS: These findings implicate mucoinflammatory processes in the CF lung as pathogenic in the absence of clinically apparent bacterial and fungal infections.
Authors: P Sharma; L Dudus; P A Nielsen; H Clausen; J R Yankaskas; M A Hollingsworth; J F Engelhardt Journal: Am J Respir Cell Mol Biol Date: 1998-07 Impact factor: 6.914
Authors: Mehmet Kesimer; Amina A Ford; Agathe Ceppe; Giorgia Radicioni; Rui Cao; C William Davis; Claire M Doerschuk; Neil E Alexis; Wayne H Anderson; Ashley G Henderson; R Graham Barr; Eugene R Bleecker; Stephanie A Christenson; Christopher B Cooper; MeiLan K Han; Nadia N Hansel; Annette T Hastie; Eric A Hoffman; Richard E Kanner; Fernando Martinez; Robert Paine; Prescott G Woodruff; Wanda K O'Neal; Richard C Boucher Journal: N Engl J Med Date: 2017-09-07 Impact factor: 91.245
Authors: Stefanie Gehrig; Julia Duerr; Michael Weitnauer; Claudius J Wagner; Simon Y Graeber; Jolanthe Schatterny; Stephanie Hirtz; Abderrazzaq Belaaouaj; Alexander H Dalpke; Carsten Schultz; Marcus A Mall Journal: Am J Respir Crit Care Med Date: 2014-05-01 Impact factor: 21.405
Authors: Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan Journal: Am J Respir Crit Care Med Date: 2009-04-16 Impact factor: 21.405
Authors: Yan Shin J Liao; Shin Ping Kuan; Maria V Guevara; Emily N Collins; Kalina R Atanasova; Joshua S Dadural; Kevin Vogt; Veronica Schurmann; Laura Bravo; Eda Eken; Mariana Sponchiado; Leah R Reznikov Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-03-11 Impact factor: 5.464
Authors: Jinghui Gao; Sophia Petraki; Xingshen Sun; Leonard A Brooks; Thomas J Lynch; Chih-Lin Hsieh; Reem Elteriefi; Zareeb Lorenzana; Vasu Punj; John F Engelhardt; Kalpaj R Parekh; Amy L Ryan Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-02-19 Impact factor: 5.464
Authors: Charles R Esther; Marianne S Muhlebach; Camille Ehre; David B Hill; Matthew C Wolfgang; Mehmet Kesimer; Kathryn A Ramsey; Matthew R Markovetz; Ian C Garbarine; M Gregory Forest; Ian Seim; Bryan Zorn; Cameron B Morrison; Martial F Delion; William R Thelin; Diane Villalon; Juan R Sabater; Lidija Turkovic; Sarath Ranganathan; Stephen M Stick; Richard C Boucher Journal: Sci Transl Med Date: 2019-04-03 Impact factor: 17.956
Authors: Hamed Horati; Hettie M Janssens; Camilla Margaroli; Mieke Veltman; Marta Stolarczyk; Matthew B Kilgore; Jeffrey Chou; Limin Peng; Harm A M W Tiddens; Joshua D Chandler; Rabindra Tirouvanziam; Bob J Scholte Journal: J Cyst Fibros Date: 2020-02-10 Impact factor: 5.482
Authors: Camilla Margaroli; Luke W Garratt; Hamed Horati; A Susanne Dittrich; Timothy Rosenow; Samuel T Montgomery; Dario L Frey; Milton R Brown; Carsten Schultz; Lokesh Guglani; Anthony Kicic; Limin Peng; Bob J Scholte; Marcus A Mall; Hettie M Janssens; Stephen M Stick; Rabindra Tirouvanziam Journal: Am J Respir Crit Care Med Date: 2019-04-01 Impact factor: 21.405